Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential long-acting risperidone microspheres to paliperidone palmitate in schizophrenia
ChiCTR2500106570Phase 4Not yet recruiting
- Sponsor
- Shanghai Mental Health Center
- Start
- Jul 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of paliperidone palmitate in schizophrenia, sponsored by Shanghai Mental Health Center. Primary endpoint: Medication Satisfaction Questionnaire (MSQ) score. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on ChiCTR2500106570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106570.